How can an angel evaluate the execution gaps in a healthcare software startup?

Evaluate the team against the work required to reach the next milestone. Credentials and confidence are incomplete evidence of execution. Look for relevant completed work, learning behavior, responsibility allocation, and gaps that the financing plan must address.

Start with the decision

Map the critical tasks to owners and capabilities. Ask for examples of a difficult decision, a failed assumption, and a change made after evidence. Use permissioned references and avoid judging personal characteristics unrelated to the investment question.

The illustrative scenario

This is an educational workbook. The company or fund and all numerical inputs below are fictional. They are not ADIN results, customer claims, market benchmarks, or a forecast.

The fictional team is piloting an administrative scheduling product with a provider group. Staff use it in a narrow workflow, while procurement and data review determine whether a broader rollout is possible.

A clinic's enthusiasm does not resolve data handling, workflow ownership, or applicable regulatory questions. This example does not assume a particular legal classification or approval.

Turn the scenario into an evidence decision

Consider a review of a healthcare software startup in which a confident explanation arrives before the supporting records. Start with the first question in the table. Write down what an answer would change: the next interview, the experiment's scope, a request for specialist review, or a decision to wait. A question without a consequence can produce a longer document while adding little understanding.

Next, inspect the record named in the table and record its date, owner, permission boundary, and limitations. Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet. If the record contradicts the explanation, preserve both accounts and ask which definition, period, or workflow differs. Do not silently select the version that makes the opportunity look strongest.

Finish with a conditional statement: if the specified evidence supports the claim under these conditions, take the named next step; otherwise investigate the unresolved question. A capable team can still face an infeasible plan. Connect the assessment to product, customer, and cash constraints instead of assigning a generic founder score that conceals the specific risk. This worked exercise is about the decision process. It does not assert that a fictional company has met a real diligence standard or that a template can authorize an investment.

Use this worksheet

Answer the questions with a source, date, owner, and next action. Mark an unknown as unknown. Use public or permissioned information and involve a qualified specialist when a question requires expertise beyond the team’s competence.

1. What work has the team completed?
2. Who owns the critical task?
3. Which capability is missing?
4. How does the team respond to evidence?
5. What dependency remains concentrated?

Questions specific to this scenario

• Which workflow is actually in scope?
• Who approves data access?
• What specialist review is needed?

Review authorized workflow observations, procurement requirements, permissioned usage evidence, and specialist advice about applicable obligations. Avoid using identifiable patient information in a diligence packet.

A concrete next test

Ask the authorized workflow owner to map a narrow administrative use case without disclosing patient information. Identify the data-access and procurement approvals needed for the next step. Keep operational adoption evidence separate from claims about clinical benefit or regulatory status.

Interpret the result

A capable team can still face an infeasible plan. Connect the assessment to product, customer, and cash constraints instead of assigning a generic founder score that conceals the specific risk.

Compare the administrative workflow and rollout dependencies with the current process. Do not treat an operational pilot as clinical efficacy evidence.

Sources and method

These primary resources provide background for the concepts. The fictional scenario, calculations, and worksheet are ADIN educational examples; the sources do not report or validate those invented results. Reviewed October 11, 2026.

• Angel Capital Association: Knowledge Center
• Investor.gov: Private Equity Funds